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Summary (416 words) 
Background: Use of maintenance antibiotic therapy with the macrolide azithromycin is increasing 
in different chronic respiratory disorders including primary ciliary dyskinesia (PCD). However, 
evidence for its efficacy in PCD is lacking. We aimed to determine efficacy and safety of 
azithromycin maintenance therapy for 6 months in patients with PCD. 
Methods: The BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary 
Dyskinesia) trial was a multi-centre, double-blind, parallel group, randomised, placebo-controlled 
phase 3 trial at 6 European PCD clinics at tertiary paediatric level and university hospitals (Denmark, 
Germany, Netherlands, Switzerland, and United Kingdom). Patients with a confirmed diagnosis of 
PCD, aged 7-50 years, and FEV1 >40% predicted, were recruited. Participants were randomly 
assigned (1:1), stratified by age and study site, via a web-based randomisation system to azithromycin 
250 or 500 mg as tablets according to body weight (</≥ 40 kg) or identical placebo, three times a 
week for 6 months. The random allocation sequence was a permuted block randomisation, with a 
block size of four, generated by an external consultancy. Participants, investigators, and care 
providers were masked to treatment allocation. The primary endpoint was the number of respiratory 
system exacerbations over 6 months. Analysis was by intention-to-treat. This study is registered in 
the European Union Clinical Trials Register, number 2013-004664-58. 
Findings: Between June 24, 2014, and August 23, 2016, 102 patients were screened, of whom 90 
were randomly assigned to either azithromycin (n=49) or placebo (n=41). The study was ended 
without having included the planned number of participants due to recruitment difficulties. The mean 
(SD) number of respiratory system exacerbations over 6 months was 0·75 (1·12) in the azithromycin 
group compared to 1·62 (1·64) in the placebo group, and participants receiving azithromycin had 
significantly lower rate of exacerbations during the individual treatment periods (rate ratio [95% CI]: 
0·45 [0·26-0·78], p=0·004). In total, four serious adverse events were reported, occurring in one 
(2·1%) of 47 participants in the azithromycin group and in three (7·3%) of 41 participants in the 
placebo group. Loose stools or diarrhoea were more common in the azithromycin group than in the 
placebo group (11 [23·4%] vs two [4·9%]). 
Interpretation: This first multi-national randomised controlled trial on pharmacotherapy in PCD 
showed that azithromycin maintenance therapy for 6 months was well tolerated and halved the rate 
of respiratory exacerbations. Azithromycin maintenance therapy is an option for PCD patients with 
frequent exacerbations potentially leading to reduced need for additional antibiotic treatments and 
preventing irreversible lung damage.  











Research in context 
Evidence before this study 
There is a substantial need for evidence-based guidelines specifically for the management of PCD -
given that current treatment strategies must be extrapolated from other chronic respiratory diseases, 
notably cystic fibrosis and non-cystic fibrosis bronchiectasis. Before undertaking this study, we 
searched the literature via PubMed in 2013 for clinical trials on pharmacotherapeutics for PCD and 
randomised controlled trials of azithromycin maintenance therapy for non-cystic fibrosis 
bronchiectasis. We combined the search terms: “primary ciliary dyskinesia” with “randomized”, and 
“azithromycin” with “randomized” and “non-cystic fibrosis bronchiectasis”, without restrictions in 
publication date or language to optimize the search. The search for clinical trials investigating 
possible pharmacotherapeutics for PCD yielded only three randomised studies, none of which 
investigated antibiotics. In addition, we were aware of one ongoing trial investigating hypertonic 
saline in PCD. The search for randomised controlled trials with maintenance azithromycin for non-
cystic fibrosis bronchiectasis revealed two studies in adult patients lasting 6 and 12 months, 
respectively, and one study in Indigenous children with non-cystic fibrosis bronchiectasis or chronic 
suppurative lung disease (PCD not excluded as possible aetiology of bronchiectasis). These studies 
found that azithromycin decreased exacerbations, and in adult patients, it also improved lung function 
and health-related quality of life after 12 months of intervention.  
Added value of this study 
The BESTCILIA study is the first clinical trial in PCD investigating efficacy of maintenance 
antibiotics. Azithromycin maintenance therapy for 6 months did significantly reduce respiratory 
system exacerbations in PCD, compared to placebo, and was well tolerated. The study also 
demonstrated that maintenance azithromycin more than halved the detection rate of pathogenic 
bacterial species in sputum in PCD.  
Implications of all the available evidence 
This study shows that azithromycin maintenance therapy reduces exacerbations in PCD, which is in 
complete agreement with previously published results within non-cystic fibrosis bronchiectasis and 
other chronic respiratory disorders. These study results are the first step towards the development of 
evidence-based guidelines on pharmacotherapy for PCD. Maintenance azithromycin should now be 
considered as a treatment option for PCD patients with frequent exacerbations, possibly reducing the 
need for additional antibiotic treatments and might as a logical consequence also reduce progression 
in lung damage. In a next step studies investigating both maintenance azithromycin over a prolonged 








Introduction (body: 5678 words) 
Primary ciliary dyskinesia (PCD) is a rare, genetically and clinically heterogeneous disease that 
manifests from the neonatal period or early childhood and progresses through adulthood.1 Impaired 
mucociliary clearance due to abnormal ciliary beating results in excessive accumulation of mucus 
and bacteria in the upper and lower airways.2 PCD is a suppurative disease characterised by chronic 
rhino-sinusitis, recurrent otitis media and conductive hearing impairment, chronic productive cough 
and infections in the lower airways.1,3,4 Recurrent lower respiratory tract infections lead to chronic 
infection, bronchiectasis and decline in lung function.1,3,5 
The treatment strategies for PCD have been extrapolated from more common chronic respiratory 
diseases with different pathophysiologies, notably cystic fibrosis and non-cystic fibrosis 
bronchiectasis. No orphan drugs have been developed for PCD.3,6-8 Only two published randomised 
controlled studies have investigated the efficacy and safety of pharmacotherapeutics used in the 
treatment of PCD – inhaled hypertonic saline and salbutamol, respectively – but found no significant 
change in the primary outcomes, which were quality of life measured by the St George’s Respiratory 
Questionnaire total score in the study with hypertonic saline and forced expiratory volume in one 
second (FEV1) and parameters of bronchial responsiveness in the study with salbutamol.9,10 
Importantly, it has been difficult to develop evidence-based guidelines for the treatment of PCD 
because of the paucity of clinical studies, and the scientific evidence for effective treatments is simply 
lacking in PCD.3,8 Treatment approaches for PCD have, accordingly, varied widely both within and 
between European countries.6 Evidence-based treatments for PCD are urgently needed to reduce the 
morbidity of this lifelong disease and its impacts on quality of life. 
Maintenance therapy with macrolide antibiotics has been evaluated in several chronic respiratory 
disorders, following evidence of effectiveness in long-term treatment with erythromycin for those 
with diffuse panbronchiolitis.11 The macrolide azithromycin has, in addition to its bacteriostatic 
effects, beneficial anti-inflammatory properties and properties regarding quorum sensing 
inhibition.12,13 In cystic fibrosis, azithromycin maintenance therapy improved FEV1 with 4% over 6 
months and reduced the use of additional oral antibiotics, compared to placebo (odds ratio 0·28, 95% 
confidence interval [CI] 0·19-0·42). Patients receiving azithromycin were twice as likely to be free 
of pulmonary exacerbations.14 Two randomised placebo-controlled trials evaluating azithromycin 
maintenance therapy for 6 and 12 months, respectively, in adult patients with non-cystic fibrosis 
bronchiectasis demonstrated decreases in exacerbations, rate ratio 0·38, 95% CI 0·26-0·54 over 6 
months and 0 exacerbations (interquartile range [IQR], 0-1), compared with 2 (IQR, 1-3) in the 
placebo group in the 12 months study,15,16 along with improvement in lung function and health-related 
quality of life.15,16  A decreased exacerbation rate was also found in Indigenous children with non-
cystic fibrosis bronchiectasis or chronic suppurative lung disease.17 Azithromycin maintenance 
therapy is increasingly being used in different chronic respiratory disorders including PCD, despite 
the lack of data on efficacy and safety. 
The BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) trial 





primary objective the number of respiratory system exacerbations and as secondary objectives lung 
function, health-related quality of life, hearing impairment, sputum microbiology, and inflammatory 
markers in patients with PCD, aged 7-50 years, and concurrently, its safety in PCD. 
 
Methods 
Study design and participants 
The BESTCILIA study was a multi-centre, double-blind, parallel group, randomised, placebo-
controlled, phase 3 trial performed at six European PCD clinics at tertiary paediatric level and 
university hospitals (Amsterdam, Netherlands; Bern, Switzerland; Copenhagen, Denmark; Muenster, 
Germany; and London and Southampton, United Kingdom). Further details of study design and 
methodology can be found in the study protocol published previously.18 
Patients were eligible for inclusion in the study if they had a confirmed diagnosis of PCD (see the 
Appendix for diagnostic criteria); were 7-50 years old; had FEV1 >40% predicted; had received at 
least 30 days of antibiotics prescribed for respiratory tract infections or exacerbations within the 
previous two years; currently received no systemic or inhaled maintenance antibiotics; and had not 
taken azithromycin within one month prior to screening. Exclusion criteria at screening were current 
infection with Achromobacter xylosoxidans or Burkholderia cepacia complex, infection with non-
tuberculous mycobacteria within 6 months, or chronic infection with Pseudomonas aeruginosa 
(defined as culture of Pseudomonas aeruginosa in ≥50% of the sputum samples within the last year, 
provided at least three sputum cultures were available). Other exclusions were: allergic reaction to 
macrolide antibiotics or other ingredients of the study drug; alanine transaminase twice or more the 
upper limit of normal or history of portal hypertension; serum creatinine >150 µmol/l or glomerular 
filtration rate <50 mL/min; prolonged QT interval, cardiac arrhythmia, severe heart failure, or 
electrolyte disturbances; myasthenia gravis; treatment with medicinal products known to possibly 
interact with azithromycin or prolong QT interval (Appendix); pregnancy, breastfeeding, or fertile 
women using unreliable contraception; or home oxygen or assisted ventilation.  
The study was approved by the ethics committees at the participating institutions and the national 
competent authorities in the participating countries. The study was performed in accordance with the 
Declaration of Helsinki and Good Clinical Practice. All patients and/or parents on behalf of their 
children provided written informed consent prior to inclusion. 
The study was monitored by regional good clinical practice monitors.  
Randomisation and masking 
Participants were randomly assigned to azithromycin or placebo (1:1), stratified by age (7·0-12 years; 
13·0-21 years; and 22·0-50 years) and study site (the anticipated three least recruiting study sites 
comprising the sites in Bern, Amsterdam, and Southampton were merged for stratification purposes 





with block size of four, which had been generated by an external consultancy (DEFACTUM, Central 
Denmark Region, Aarhus, Denmark). Block size was not masked to study personnel. A web-based 
data and randomisation system (‘TrialPartner’, DEFACTUM, Central Denmark Region, Aarhus, 
Denmark) was used for randomisation by delegated study staff. The study drug was prepared by a 
Good Manufacturing Practice certified hospital pharmacy (Apotheek Haagse Ziekenhuizen, Haag, 
Netherlands), who bought the azithromycin tablets from a pharmaceutical company and 
manufactured identical placebo tablets. Blinded packaging and labelling of the study drugs were 
performed centrally at the hospital pharmacy before delivery to the study sites. Participants, 
investigators, study personnel, and care providers were masked to treatment allocation until after the 
end of the trial. 
Procedures 
The intervention was oral tablets of azithromycin 250/500 mg according to body weight (</≥ 40 kg) 
or identical tablets of placebo, self-administered three times a week (Monday-Wednesday-Friday) for 
six months. Pre-study medication continued unchanged, except for maintenance antibiotics and 
certain prohibited medications (Appendix). Additional systemic and inhaled antibiotic treatment was 
allowed during clinical exacerbations and in case of infection with Pseudomonas aeruginosa, 
Achromobacter xylosoxidans, or Burkholderia cepacia complex emerged during the study. Treatment 
with the study drug continued simultaneously with antibiotics prescribed for exacerbations and 
infections. 
Patients were screened for eligibility and randomised in a clinically stable state. Screening included 
spirometry, electrocardiogram to exclude arrhythmias and prolonged QT interval, and sputum 
analysis to exclude non-tuberculous mycobacteria. Screening was followed by a one-month run-in 
period to ensure stable lung function (maximal decrease in FEV1 percent predicted of 10 %-points 
from screening to randomisation) and washout of any prohibited medications. Patients were 
withdrawn from the study if they received antibiotics to treat an exacerbation or infection for more 
than 14 days during the run-in period. Study visits were scheduled every second month during the 
treatment period (at 2 months, 4 months and 6 months). Patients were instructed to contact the study 
sites in-between their scheduled study visits if they experienced symptoms of exacerbation and 
complete a weekly diary card on symptoms and antibiotic use. All study visits included assessments 
of symptoms of exacerbation, adverse events, and concomitant medications, a physical examination 
including vital signs, completion of the newly developed and validated PCD-specific health-related 
quality of life questionnaire (QOL-PCD),19-22 nitrogen multiple breath washout (N2 MBW) using 
identical equipment and software versions across all sites, spirometry, body plethysmography, 
sputum culture and susceptibility testing, and urine pregnancy test in all sexually active, fertile 
women. Additional tests performed at the randomisation visit and at the 6-month final study visit 
were audiometry and tympanometry, blood tests (haematology, C-reactive protein, kidney- and liver 
function), and sampling of serum and sputum for later centralised analysis of cytokines (see Schedule 
of assessments – table A2 in the Appendix). Adherence with study drug was assessed by count of 
returned study drugs and participant/parent report. All adverse events, regardless of severity or 





withdrawal from the study were recorded. Patients were withdrawn during the study if they met the 
safety-related exclusion criteria, were lost to follow-up, withdrew consent, had poor compliance, 
developed infection with non-tuberculous mycobacteria, used prohibited medications, or reported 
serious or intolerable adverse reactions.  
The following changes to the eligibility criteria were made after initiation of the study: The age range 
was increased to 50 years of age from an originally maximum age of 40 years due to recruitment 
difficulties; participants were allowed to use local maintenance antibiotics e.g. antibiotic cream, 
except from inhaled antibiotics, since this was not considered to affect the endpoints; and up to 14 
days antibiotic treatment (except macrolide antibiotics) was allowed throughout the run-in period). 
Originally, no changes in antibiotics or respiratory medicine were allowed during the run-in period 
but this turned out to be untenable in PCD. These protocol amendments were approved by the ethics 
committees and the competent authorities in 2015.   
Outcomes 
The primary outcome was number of respiratory system exacerbations over 6 months. A per-protocol 
respiratory system exacerbation was defined as any respiratory tract symptoms leading to initiation 
of systemic antibiotics, irrespective of results of bacterial culture, or decline in FEV1 percent 
predicted ≥10 %-points relative to the average of FEV1 percent predicted at screening and 
randomisation,23 whether antibiotics were prescribed or not. All exacerbations were reviewed by the 
coordinating investigator team prior to database lock and unmasking of the treatment allocations to 
ensure that they were in accordance with the above definition.  
Secondary outcomes were:18 changes over 6 months in FEV1, forced vital capacity (FVC), and forced 
expiratory flow at 25-75% of FVC (FEF25-75) in percent predicted;23 residual volume (RV), RV/total 
lung capacity (TLC), and airway resistance (Raw) in percent predicted;24,25 lung clearance index 
(LCI) and the indices Scond*VT and Sacin*VT in absolute values, derived from N2 MBW; and the three 
symptom scales from the QOL-PCD instrument (Respiratory Symptoms, Sinus Symptoms, and Ears 
& Hearing Symptoms); changes from baseline to six months in pure tone average and discrimination 
loss, measured by audiometry; tympanograms; and in inflammatory markers (white blood cells 
including differential cell counts, C-reactive protein, the cytokines interleukin-1 beta (IL-1β), 
granulocyte-colony stimulating factor (G-CSF), and interleukin-8 (IL-8) in serum, and the cytokines 
IL-1β, G-CSF, IL-8, interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), growth-regulated 
oncogene alpha (Gro-Alpha), and monocyte chemoattractant protein-1 (MCP-1) in sputum); sputum 
microbiology (number of pathogenic airway bacterial species and resistance to macrolides); and 
adverse events and serious adverse events. Time of assessment of the outcomes is showed in table 
A3 in the Appendix. 
After trial commencement the protocol was amended with regard to the primary outcome, because 
the original definition was too narrow to include all the desired cases of this variable. Originally, the 
definition of the primary outcome was “respiratory tract symptoms leading to prescription of 
antibiotic treatment by either an investigator or another physician consulted by the subject”. However, 





symptoms of exacerbation, before consulting a physician – so therefore the requirement of 
prescription of the antibiotics by a physician was deleted from the protocol. No changes were made 
to the part of the primary outcome concerning decline in FEV1. Total and differential cell count in 
sputum was originally part of the secondary outcome on inflammatory markers but was deleted from 
the protocol because it was considered complicated to perform uniformly among the study sites. The 
protocol amendment was performed during the recruitment period of the study and approved by the 
ethics committees and the competent authorities in 2015. 
 
Statistical analysis 
The sample size calculation estimated that 50 patients per treatment group would have to complete 
the study to have 90% power to detect a 50% reduction in rate of exacerbations in the treatment period 
in the azithromycin group (corresponding to a rate ratio of 0·50) - assuming a mean of 2·5 
exacerbations per year in the placebo group, using the Poisson distribution and a two-sided α level of 
0·05. Estimating a 20% drop-out, 125 patients would have to be randomised. The power would be 
70% to detect a between-group difference of five percentage points in the pre- to post-intervention 
change in FEV1 percent predicted (assuming a SD of 10% for intra-subject change)26 and 88% to 
detect a similar between-group difference in LCI (assuming a SD of 8% for intra-subject change). 
The assumptions utilized for the sample size calculations were based on experience and consensus 
among experts in the BESTCILIA consortium, since no published evidence existed on the yearly rate 
of exacerbations or trend in spirometric lung function and ventilation inhomogeneity in PCD at the 
time the study protocol was elaborated. The rationale for the aim of detecting a 50% reduction in 
exacerbations in the azithromycin group was based on findings in randomized placebo-controlled 
studies with azithromycin maintenance therapy in non-cystic fibrosis bronchiectasis15 and cystic 
fibrosis.27,28Analyses were based on the intention-to-treat population, defined as all randomised 
patients, except for analyses of sputum microbiology, hearing outcomes, and inflammatory markers, 
that were based on a modified intention-to-treat population to include all patients with relevant 
follow-up visits. Data from drop-outs were included in the analyses when available. The safety 
analysis population included all patients who received at least one dose of assigned treatment.  
The rate of exacerbations (primary outcome) and the rate of bacterial species in sputum (secondary 
outcome) in the two treatment groups were compared using the negative binomial distribution. The 
negative binomial distribution provided the best fit to the data in terms of the Akaike information 
criterion compared to other distributions for count data (the Poisson, zero-inflated Poisson and 
negative binomial, hurdle Poisson and negative binomial). The number of days from baseline to end 
of follow-up was used as an offset variable and the analyses were adjusted for the stratification 
variables (age in groups and study site). For each group, the mean and SD of the primary outcome at 
6 months follow-up were determined from the negative binomial distribution using as offset the 
number of days from baseline to end of follow-up scaled to 6 months. As supplementary analyses, 
the probability of remaining free of exacerbations and the probability of drop-out were determined 





Between-group differences in the quantitative secondary outcomes over the 6 months treatment 
period were assessed using linear mixed models. The fixed part of the models included the interaction 
between treatment group and visit as qualitative explanatory variable with the constraint that the 
means in the two treatment groups were assumed equal at baseline due to randomisation. The random 
part of the model included a random intercept for each patient. In the analyses of the hearing 
outcomes, an additional random effect of ear within individual was included as measurements were 
taken on both the left and right ear. All analyses were adjusted for the stratification variables as fixed 
effects. The linear mixed effects models of the QOL-PCD outcomes were adjusted for the age-
appropriate versions of the QOL-PCD instead of the stratifying age variable.   
Tympanograms, a secondary outcome was redefined as a binary variable, where A-curves represented 
‘normal’ and B- and C-curves were combined to represent ‘abnormal’ and analysed using logistic 
regression model with estimates obtained from generalized estimating equations with an unstructured 
working correlation matrix. Adverse events and macrolide-resistance that emerged during the 6 
months treatment period were compared in the two groups by Chi-Square test or Fisher’s Exact test, 
as appropriate. 
Two-sided p-values <0·05 were considered statistically significant. The statistical analyses were 
performed in R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) and in SAS 
version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). 
 
This study is registered in the European Union Clinical Trials Register, number 2013-004664-58. 
 
Role of the funding source 
The financial sponsors of the study had no role in study design, data collection, analysis, interpretation 
of the data, or in writing of the report. HEK, FFB and KGN had access to the raw data. The 




Between June 24, 2014, and August 23, 2016, 102 patients were screened, of whom 90 were randomly 
assigned to receive either azithromycin (n=49) or placebo (n=41) (figure 1). Follow-up of the last 
participant ended in May 2017. The study was ended without having included the planned number of 
participants due to recruitment difficulties,18 despite a prolonged recruitment period, and lack of 
funding. The decision to terminate the study prematurely (in regard of the planned number of 
participants) was made by the coordinating investigator team and the principal investigators. No 
interim analyses or renewed power calculations had been performed at the time the study was 
terminated. The treatment groups had very similar baseline characteristics (table 1), except lower 
mean Raw percent predicted in the azithromycin group than in the placebo group (126·2 vs 147·6), 
higher mean Respiratory symptom scores on the QOL-PCD in the azithromycin group (67·31 vs 
59·40), and lower parent proxy scores on the Sinus symptoms and Ear & Hearing symptoms scales 





withdrew from the study over the 6 months treatment period. The reasons for drop-out in the two 
treatment groups are stated in figure 1. There was no difference in the cumulative probability of drop-
out between the two groups (p=0·6). 
In total, 87 events fulfilled the per-protocol definition of a respiratory system exacerbation (31 events 
in the group receiving azithromycin and 56 in the placebo group). The mean (SD) number of 
respiratory system exacerbations over 6 months was 0·75 (1·12) in the azithromycin group compared 
to 1·62 (1·64) in the placebo group. Patients receiving azithromycin had a significantly lower rate of 
exacerbations during the individual treatment periods [rate ratio (95% CI): 0·45 (0·26-0·78), 
p=0·004], compared to those receiving placebo. The cumulative number of respiratory system 
exacerbations per treatment group from baseline to the last observed visit per individual is visualized 
in figure 2. The probability of remaining free of respiratory system exacerbations was 57% (95% CI: 
44-75%) in the azithromycin group compared to 30% (95% CI: 17-51%) in the placebo group at 180 
days of follow up. The probability of remaining free of exacerbations during the follow-up was thus 
clearly in favour of azithromycin (p=0·01) as shown in figure 3. 
Change in FEV1 percent predicted over 6 months did not differ between the groups (at the 6-month 
visit, a mean (95% CI) between-group difference of 3·09 (0·18-6·00), p=0·0375, was found; however, 
no trends were apparent at the 2-month and 4-month visits and the  p-value should be considered in 
light of the multiple testing. There were no between-group differences in FVC or FEF25-75 percent 
predicted, nor in the plethysmographic outcomes or ventilation inhomogeneity indices: RV, RV/TLC, 
and Raw percent predicted, LCI, Scond*VT, and Sacin*VT (table 2 and Appendix table A5). 
There were no statistically significant between-group differences in changes over 6 months in the 
three pre-specified endpoints from the QOL-PCD instrument: respiratory symptoms, sinus symptoms, 
and ear & hearing symptoms (table 2 and Appendix table A5). 
Changes in hearing outcomes and inflammatory markers (peripheral blood cells, C-reactive protein, 
and cytokines in serum and sputum) from baseline to the 6-month visit did not differ between the 
treatment groups (table 2 and Appendix table A6). 
In total, 224 sputum cultures were available from the three scheduled follow-up visits, of which 90 
(40·2%) were positive for pathogenic airway bacteria and 75 (83·3%) of these were tested for 
susceptibility to macrolides. Occurrence of pathogenic airway bacteria at baseline, at the 6-month 
visit, and bacteria that emerged during the 6 months treatment period are shown in table 3. The mean 
(SD) number of pathogenic airway bacterial species over the individual treatment periods was 0·93 
(1·37) in the azithromycin group versus 2·41 (2·18) in the placebo group, demonstrating a significant 
difference in favour of the azithromycin group [mean (95% CI) difference: 1·47 (0·65-2·30), 
p=0.0007]. The detection rate of pathogenic bacterial species during the individual treatment periods 
was significantly lower in the azithromycin group compared to the placebo group [rate ratio (95% 
CI): 0·34 (0·21-0·54), p<1e-04]. Twenty-six (57·8%) of 45 participants in the azithromycin group 
had no pathogenic airway bacteria in sputum over the individual treatment periods compared to eight 
(21·6%) of 37 participants in the placebo group. Figure 4 shows the cumulative number of pathogenic 





Serious adverse events were reported in four participants: Two participants (one from each group) 
were admitted to hospital for a per-protocol respiratory system exacerbation requiring intravenous 
antibiotics; one participant from the placebo group was admitted to hospital due to upper abdominal 
pain which resolved without treatment; and another participant from the placebo group was 
hospitalized for surgical removal of an ovarian cyst, which turned out to be a teratoma. Excluding 
per-protocol respiratory system exacerbations, any adverse event was reported by 37 (78·7%) of 47 
participants in the azithromycin group versus 31 (75·6%) of 41 participants in the placebo group. The 
most common adverse events are listed in table 4. Loose stools or diarrhoea were reported more 
frequently in the azithromycin than placebo group (11 [23·4%] of 47 participants vs 2 [4·9%] of 41 
participants, p=0.017). Four participants had self-reported auditory complaints: One from each group 
reported (increased) hearing impairment as a separate symptom (not part of exacerbation or middle 
ear inflammation), and one of these participants plus another two participants (azithromycin group) 
reported tinnitus or worsening of tinnitus. Six participants (two in azithromycin group and four in 
placebo group) had an increase in hearing threshold of ≥5 dB after the 6-month treatment period, of 
which two (placebo group) had hearing threshold above the normal range (>25 dB). Alanine 
transaminase increased to abnormal values from baseline to the 6-month visit in three participants; 
However, only one participant (azithromycin group) had a value more than twice the upper limit of 
normal. Three participants (two from azithromycin group and one from placebo group) had mild or 
moderate eosinophilia after the 6 months treatment period. No participants developed leukopenia, 
neutropenia, or abnormal increase in creatinine. From the placebo group, two participants were 
withdrawn due to suspected or verified non-tuberculous mycobacteria and one participant had a 
positive sputum culture for Mycobacterium gordonae within a month after he had ended the study. 
There were no significant between-group differences in the emergence of macrolide-resistant 
pathogenic airway bacteria (table 3). 
 
Discussion  
This first ever multi-national randomised controlled trial in PCD evaluated the efficacy and safety of 
an increasingly prescribed maintenance therapy with the potential to provide evidence-based 
treatment for this lifelong respiratory disease. Azithromycin maintenance therapy for 6 months in 
PCD significantly reduced the rate of respiratory system exacerbations to half, compared to placebo. 
By decreasing the rate of exacerbations, azithromycin prevents potentially irreversible declines in 
lung function and reduces the need for additional antibiotic treatments.29 The only secondary outcome 
which showed a significant between-group difference, was the rate of detected pathogenic bacterial 
species in sputum, which was more than halved by maintenance azithromycin. Azithromycin 
maintenance therapy was safe, but gastrointestinal symptoms were more common in participants 
receiving azithromycin. 
Previous randomised placebo-controlled trials in cystic fibrosis,27,28,30 non-cystic fibrosis 





efficacy of azithromycin maintenance therapy on exacerbations. The efficacy of maintenance 
azithromycin on exacerbations has now been proven also to apply to patients with PCD. 
The present study could not demonstrate any significant differences between the treatment groups in 
lung function. Similarly to our study, two placebo-controlled trials investigating maintenance 
azithromycin for 6 months in adult patients with non-cystic fibrosis bronchiectasis15 and in children 
and adolescents with cystic fibrosis not infected with Pseudomonas aeruginosa,28 respectively, found 
no significant difference between the treatment groups in FEV1, and neither any between-group 
difference in FVC or FEF25-75 in the latter study.28 In contrast, a 6-months trial in cystic fibrosis 
patients chronically infected with Pseudomonas aeruginosa30 found a significant relative 
improvement of 4·4% and 5·0% in FEV1  and FVC% predicted in the azithromycin group compared 
to the placebo group. Whether maintenance azithromycin will be able to improve lung function in 
PCD patients chronically infected with Pseudomonas aeruginosa remains to be investigated. We 
deliberately excluded patients chronically infected with Pseudomonas aeruginosa in our study 
because of huge variation in treatment practises between sites and because it was felt that chronic 
infection would introduce a high level of treatment activity, with high dose systemic antibiotic 
treatment being a critical confounder.18 The efficacy of a prolonged 12-months azithromycin 
intervention on lung function has also been evaluated in both cystic fibrosis and non-cystic fibrosis 
bronchiectasis with different results - a significant relative increase in FEV1 and FVC % predicted of 
1·13% and 1·63% per 3 months were seen in adult non-cystic fibrosis bronchiectasis (one PCD patient 
included),16 whereas no between-group difference in FEV1 and FVC was found in children and 
adolescents with cystic fibrosis.27 We speculate that a longer intervention period with azithromycin 
therapy will be required to significantly change lung function in PCD patients - as was the case in 
non-cystic fibrosis bronchiectasis – because the annual decline in lung function after diagnosis is on 
average of limited size.5,32 
A secondary focus of this study was evaluation of new outcome measures in PCD. We included MBW 
indices and symptom scales on the newly developed PCD-specific health-related quality of life 
instrument as outcome measures for the first time in PCD. Mild to severe ventilation inhomogeneity 
has been demonstrated in PCD, even in patients with FEV1 within the normal range,33 and a minimal, 
but significant increase in LCI in children and young adults has been observed over a 1-year period.34 
The LCI is increasingly utilized as outcome in cystic fibrosis, where it has shown potential as outcome 
measure in mild cystic fibrosis.35 However, we could not demonstrate any between-group difference 
in LCI or the indices of regional ventilation inhomogeneity in this study. None of the previous trials 
with maintenance azithromycin have explored MBW indices as outcome measures. As with 
spirometric lung function, we speculate that a treatment period of 6 months azithromycin may be too 
short to significantly improve ventilation inhomogeneity.  
Contrary to our hypothesis, we could not show efficacy of 6 months azithromycin maintenance 
therapy on the pre-specified endpoints from the QOL-PCD instrument. A possible explanation why 
we were not able to demonstrate any difference between the treatment groups, may be that the 
participants had high mean scores at baseline, which makes it more difficult to improve the scores 





versions due to the limited number of participants in each age group, although the versions do not 
contain the exact same items or same number of items.21,22 We consider the pooled analysis approach 
necessary if the QOL-PCD is to be used as outcome measure in smaller clinical trials including a 
wide age range, which will likely also be the case for many future trials in PCD due to the rarity and 
relatively late diagnosis of the disease. In adult non-cystic fibrosis bronchiectasis patients, a placebo-
controlled trial with 6-months azithromycin15 did not show significant difference in health-related 
quality of life in terms of total score on the St George’s respiratory questionnaire, but found a 
borderline significant improvement in the symptom component of the questionnaire in the 
azithromycin group, and a similar 12-month study16 showed improvement in total score on the St 
George’s respiratory questionnaire. The length of the azithromycin intervention therefore could be 
suspected to influence change in quality of life. However, in children and adolescents with cystic 
fibrosis, no significant between-group difference in either total score or the physical and psychosocial 
scores on the cystic fibrosis quality of life questionnaire was seen over 12-months azithromycin 
treatment.27 We would expect that an intervention period of 6 months azithromycin should be 
sufficient to demonstrate improvement in the symptom scales on the QOL-PCD. 
Similarly, to some of the previous clinical trials with maintenance azithromycin, mild gastrointestinal 
symptoms were overrepresented in the participants receiving azithromycin.15,16,30 Gastrointestinal 
complaints only very rarely led to discontinuation of study drug or withdrawal,15,16,30 and thus could 
be considered as mild and partially expected. No increased frequency of hearing loss was seen in the 
azithromycin group in our study, though this has been found in older patients with chronic obstructive 
pulmonary disease;31 However, a few participants receiving azithromycin reported tinnitus or 
worsening of tinnitus. Concern about increased macrolide-resistance among common respiratory 
pathogens has been raised based on previous trials with maintenance azithromycin, in most cases 
lasting 12 months or longer.16,17,28,31 The present study confirmed that macrolide-susceptibility testing 
of airway bacteria should be performed on a regular basis in patients receiving maintenance 
azithromycin. As our study showed a reduction in rate of pathogenic bacterial species in sputum of 
more than 50% in the PCD patients receiving azithromycin, and since the macrolide-resistant bacteria 
can be eradicated with other commonly used antibiotics, we do not consider increased emergence of 
macrolide-resistant bacteria as a contraindication to maintenance azithromycin. Screening and post-
treatment testing for non-tuberculous mycobacteria was performed due to speculations that long-term 
azithromycin may predispose to infection with non-tuberculous mycobacteria36 and resulted in a few 
positive tests (all in the placebo group). This highlights the importance of screening for non-
tuberculous mycobacteria in PCD and to perform such screening before starting long-term 
azithromycin treatment.  
The strengths of the BESTCILIA-WP5 study include the double-blinded, multicentre and controlled 
design, and the large sample size for a trial in this relatively rare disease. To our knowledge, this is 
the first clinical trial in PCD confirming a hypothesis on the treatment of this disease by showing 
significant change in the primary outcome, and thus the first study in PCD leading to change in disease 
management and outcome. Reduction in exacerbation rates might potentially prevent progression of 
lung damage and lung function will probably be better sustained in the long term. Regarding the 





the high percentage of airway bacteria tested for macrolide-susceptibility. The main limitation of the 
study is that we were not able to include the planned number of participants. Despite this, a highly 
significant reduction in the primary outcome in the azithromycin group compared to the placebo 
group was still obtained, which may be explained by a higher frequency of exacerbations in the 
placebo group than assumed in the sample size calculation and by the reduction in exacerbations with 
azithromycin being a little more than the anticipated 50%. We do not expect that having obtained the 
planned number of participants would change the results of the secondary outcomes, since there were 
no trends towards significant difference in these outcome measures, except for the borderline decline 
in FEV1 percent predicted in the placebo group compared to the azithromycin group after 6 months 
treatment. Another limitation of the study is that there existed no definition of exacerbations in PCD, 
when this study was initiated. Recently, an expert consensus definition of pulmonary exacerbations 
in PCD has been published.37 However, this consensus definition only concerns pulmonary 
exacerbations. With the definition of ‘respiratory system exacerbations’ utilized in the present study, 
we aimed for a definition including exacerbation of both the upper and lower airways, since 
azithromycin has potential efficacy on both upper and lower respiratory tract morbidities. In addition, 
exacerbations in PCD often involves both, and a distinct separation between exacerbations of the 
upper and lower respiratory tract can be difficult. Performing a post hoc subgroup analysis based on 
the newly published expert consensus definition37 would be flawed as the per-protocol exacerbations 
in the present study does not in all cases include data on the criteria on which the new consensus 
definition is based. A limitation of the safety assessment of the study is that the statistical tests 
performed to evaluate between-group differences in adverse events may be considered inadequate 
since the analyses did not account for the individual treatment periods and repeated adverse events in 
each patient as we did not have accurate data on the latter. A further challenge of the study was the 
wide age range including both paediatric and adult patients, necessary due to the rarity of PCD, even 
though a multi-national set-up was organised to recruit an adequate number of patients.18 Finally, 
since PCD is a congenital disease and children do have early lung injury, we also wanted to include 
children for the purpose of providing evidence-based treatment to this age group. 
In conclusion, this randomised controlled trial is a first step towards evidence-based 
pharmacotherapies for PCD. Azithromycin maintenance therapy for 6 months halved exacerbations 
in PCD patients and was safe with only a limited tendency to emergence of macrolide-resistant 
bacteria. Maintenance azithromycin has thereby been proven to be an obvious treatment option to 
consider for patients with frequent exacerbations, where it can reduce the morbidity of exacerbations 
interrupting everyday life and the need for additional antibiotic treatments and potentially prevent or 
reduce extent of irreversible lung damage. The present study is not capable of answering the question 
on efficacy and safety of azithromycin maintenance therapy for longer periods than 6 months with 
certainty nor the question on efficacy in PCD patients with chronic Pseudomonas aeruginosa 
infection and therefore, trials investigating maintenance azithromycin for a prolonged intervention 
period and in patients with chronic Pseudomonas aeruginosa are warranted. The finding that both 
exacerbations and pathogenic bacterial species in sputum were substantially decreased by 





therapy already in infancy with a view to prevent the development of structural damage and 
bronchiectasis, while carefully observing the likely minimal side effects. 
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Female sex 22 (44·9%) 21 (51·2%) 
Age (years) 18·6 (8·9) 19·7 (10·8) 
Age groups   
 7-12 years 15 (30·6%) 11 (26·8%) 
 13-21 years 20 (40·8%) 18 (43·9%) 
 22-50 years 14 (28·6%) 12 (29·3%) 
Pulse oximetric saturation (%) 97·6 (1·6) 97·7 (1·3) 
Respiratory rate (breaths/min) 16·7 (3·8) 15·3 (3·1) 
Body mass index (kg/m2) 19·9 (3·7) 20·5 (4·1) 
Spirometric lung function   
 FEV1 % predicted* 76·9 (15·0) 76·5 (12·7) 
 FVC % predicted* 89·6 (12·9) 89·3 (13·1) 
 FEF25-75 % predicted* 57·4 (27·0) 53·4 (19·4) 
Lung volumes & resistance   
 RV % predicted† 164·5 (46·6) [47] 164·1 (50·1) [37] 
 TLC % predicted† 101·5 (14·0) [47] 99·3 (14·6) [37] 
 RV/TLC % predicted† 152·9 (35·0) [47] 159·1 (36·1) [37] 
 Raw % predicted† 126·2 (53·2) [47] 147·6 (71·1) [35] 
N2 Multiple Breath Washout indices   
 LCI (absolute values) 10·7 (2·4) [45] 11·2 (2·6) [39] 
 Scond*VT (absolute values) 0·062 (0·025) [45] 0·062 (0·028) [39] 
 Sacin*VT (absolute values) 0·157 (0·083) [45] 0·164 (0·123) [39] 
Hearing   
 Pure tone average - air conduction (dB) 21·7 (11·4) [48] 22·2 (17·0) 
 Discrimination Loss (%) 2·2 (3·9) [35] 1·6 (4·6) [30] 
Peripheral blood cells   
 White blood cells (×10⁹/mL) 8·0 (2·5) 7·9 (2·7) 
 Neutrophils (×10⁹/mL) 4·8 (2·2) [47] 4·7 (2·3) 
 Eosinophils (×10⁹/mL) 0·2 (0·2) [47] 0·2 (0·2) 
C-reactive protein (mg/L)‡ 2·9 (5·9) [47] 2·9 (4·7) 
QOL-PCD scale scores§   
 Respiratory symptoms 67·31 (16·39) [47] 59·40 (15·69) [40] 
 Sinus symptoms 61·91 (18·92) [47] 62·33 (22·55) [40] 
 Ear & Hearing symptoms 74·47 (24·10) [47] 75·00 (21·60) [40] 
 Parent proxy - Respiratory symptoms 65·81 (17·69) [13] 68·52 (19·84) [9] 
 Parent proxy - Sinus symptoms 56·41 (23·11) [13] 66·67 (26·02) [9] 
 Parent proxy - Ear & Hearing symptoms 73·50 (20·56) [13] 85·19 (13·61) [9] 
Respiratory medications   
 Any 35 (71·4%) 28 (68·3%) 
 Inhaled β2 agonists   
  Short-acting 12 (24·5%) 13 (31·7%) 
  Long-acting 5 (10·2%) 5 (12·2%) 
 Inhaled corticosteroids   
  Corticosteroid alone 4 (8·2%) 7 (17·1%) 
  Combined with long-acting β2 agonists 12 (24·5%) 8 (19·5%) 
 Inhaled anticholinergics 2 (4·1%) 0 
 Leukotriene-receptor antagonist 1 (2·0%) 1 (2·4%) 
 Mucolytic agent   
  Nebulized isotonic saline 8 (16·3%) 6 (14·6%) 
  Nebulized hypertonic saline 10 (20·4%) 9 (22·0%) 
  Dornase alfa 1 (2·0%) 1 (2·4%) 
  Other (acetylcysteine, bromhexine) 1 (2·0%) 1 (2·4%) 
 Nasal/sinus rinse (saline) 15 (30·6%) 7 (17·1%) 
 Nasal corticosteroids 9 (18·4%) 9 (22·0%) 
 Nasal xylometazoline 3 (6·1%) 0 
Data are presented as mean (SD) for quantitative variables and counts (% of total) for categorical variables. The 
number of participants available for the specific variables is stated in square brackets in the table cells if different from 
the total number of participants in the treatment group. 
*Reference values from Quanjer et al. Eur Respir J 2012.23 
†Reference values from Koopman et al. Respir Med 2011 for participants aged 7-18 years and from Verbanck et al. 







Table 2: Difference in secondary outcomes after 6 months follow-up 
  Change from baseline to 6 months (95% CI) Between-group difference 
(95% CI) 
p value 




Dynamic lung function     
 FEV1 % predicted 0·05 (-1·94 to 2·05) [40] -3·04 (-5·20 to -0·87) [34] 3·09 (0·18 to 6·00) 0·038 
       
 FVC % predicted -0·13 (-2·18 to 1·91) [40] -1·48 (-3·69 to 0·73) [34] 1·35 (-1·61 to 4·31) 0·37 
       
 FEF25-75 % predicted* 0% (-7% to 7%) [40] -9% (-16% to 2%) [34] 10% (-1% to 22%) 0·06 
       
Lung volumes     
 RV % predicted -4·98 (-15·24 to 5·29) [32] -3·12 (-13·94 to 7·71) [29] -1·86 (-16·32 to 12·60) 0·80 
       
 RV/TLC % predicted -5·69 (-13·32 to 1·94) [32] -0·55 (-8·61 to 7·50) [29] -5·14 (-15·92 to 5·64) 0·35 
       
Airway resistance     
 Raw % predicted† -0·02 (-0·27 to 0·23) [32] -0·33 (-0·59 to -0·06 [29] 0·31 (-0·05 to 0·67) 0·09 
       
Ventilation inhomogeneity     
 LCI 0·06 (-0·43 to 0·55) [36] -0·40 (-0·91 to 0·11) [33] 0·46 (-0·23 to 1·15) 0·19 
       
 Scond*VT 0·001 (-0·007 to 0·010) [36] 0·003 (-0·006 to 0·011) [32] -0·001 (-0·013 to 0·010) 0·80 
       
 Sacin*VT† -0·028 (-0·054 to -0·002) [36] 0·009 (-0·019 to 0·036) [32] -0·036 (-0·074 to 7e-04) 0·054 
       
QOL-PCD scale scores‡     
 Respiratory Symptoms 2·13 (-2·56 to 6·83) [39] 3·80 (-1·26 to 8·86) [33] -1·66 (-8·15 to 4·82) 0·61 
       
 Sinus Symptoms 3·62 (-1·51 to 8·75) [39] -0·22 (-5·76 to 5·32) [33] 3·84 (-3·39 to 11·07) 0·30 
       
 Ear & Hearing Symptoms 2·80 (-2·49 to 8·08) [39] 1·60 (-4·12 to 7·31) [33] 1·20 (-6·33 to 8·72) 0·75 
       
Hearing     
 Pure tone average (dB) -0·11 (-0·20 to -0·02) [39] -0·04 (-0·14 to 0·06) [32] 0·07 (-0·06 to 0·20) 0·30 
 Discrimination Loss (%) -1·17 (-2·29 to -0·05) [30] -0·86 (-2·03 to 0·32) [27] -0·31 (-1·85 to 1·23) 0·69 
 Tympanograms [35] [30]  0·18 
The first column shows the mean change from baseline to the 6 months follow-up visit (95% CI) in each treatment group, the second column 
the mean between-group difference (95% CI) after 6 months follow-up, and the p-value for the between-group difference. The changes and 
differences are estimated from a linear mixed model with an interaction between treatment group and follow-up visit based on all four study 
visits. The hearing outcomes were only measured at baseline and the 6 months follow-up visit. The number of participants measured at the 6 
months follow-up visit is stated in square brackets in the table cells. A table showing mean changes from baseline to follow-up and between-
group differences at all three follow-up visits (2 months, 4 months, and 6 months) is available in the Appendix (table A5). 
*FEF25-75 % predicted was log2 transformed for the analysis and has been back-transformed. The data are presented as relative changes. 
†Raw % predicted and Sacin*VT were square root transformed for the analyses and are presented on square root scale. 
‡The QOL-PCD scores are based on data from the QOL-PCD questionnaires completed by the children themselves, adolescents and adult 
participants. Data from the parent proxy version of the QOL-PCD questionnaire is not included in this table. 
FEV1=forced expiratory volume in one second. FVC=forced vital capacity. FEF25-75=forced expiratory flow at 25–75% of forced vital capacity. 
RV=residual volume. RV/TLC=residual volume divided by total lung capacity. Raw=airway resistance. LCI=lung clearance index. 
Scond*VT=regional ventilation inhomogeneity of the conducting airways corrected for tidal volume. Sacin*VT=regional ventilation inhomogeneity 
of the intra-acinar airways corrected for tidal volume. QOL-PCD=PCD-specific health-related quality of life questionnaire. 
 
 
‡At some study sites, C-reactive protein <2·5 was not measured more accurately (azithromycin group: n=13, placebo 
group: n=12). In order to calculate mean (SD), C-reactive protein was in these cases set to zero. 
§Scores range from 0 to 100, with higher scores indicating better health-related quality of life. 
FEV1=forced expiratory volume in one second. FVC=forced vital capacity. FEF25-75=forced expiratory flow at 25–
75% of forced vital capacity. RV=residual volume. RV/TLC=residual volume divided by total lung capacity. 
Raw=airway resistance. N2=nitrogen. LCI= lung clearance index. Scond*VT=regional ventilation inhomogeneity of the 
conducting airways corrected for tidal volume. Sacin*VT=regional ventilation inhomogeneity of the intra-acinar airways 





Table 3: Occurrence of pathogenic airway bacteria in sputum cultures and macrolide resistance 













Culture of pathogenic bacteria 26 (53·1%) 22 (53·7%) 11 (27·5%) 21 (61·8%)   
Haemophilus influenzae 16 (32·7%) 14 (34·1%) 6 (15·0%) 16 (47·1%) 4 (10·5%) [38] 14 (50·0%) [28] 
 macrolide-resistant H. Influenzae 1 (2·0%) 0 3 (7·5%) 1 (2·9%) 3 (6·8%) [44] 2 (5·4%) 
Streptococcus pneumoniae 11 (22·4%) 8 (19·5%) 2 (5·0%) 3 (8·8%) 2 (5·0%) [40] 5 (15·2%) [33] 
 macrolide-resistant S. pneumoniae 2 (4·1%) 0 1 (2·5%) 0 4 (9·1%) [44] 1 (2·7%) 
Moraxella catharrhalis 7 (14·3%) 5 (12·2%) 0 4 (11·8%) 0 11 (30·6%) [36] 
 macrolide-resistant M. catharralis 0 0 0 0 0 0 
Staphylococcus aureus 5 (10·2%) 3 (7·3%) 4 (10·0%) 6 (17·6%) 6 (13·6%) [44] 8 (22·2%) [36] 
 - MRSA 1 (2·0%) 0 0 0 0 1 (2·7%) 
 macrolide-resistant S. aureus 1 (2·0%) 0 3 (7·5%) 2 (5·9%) 5 (11·1%) 2 (5·4%) 
Pseudomonas aeruginosa 0 3 (7·3%) 2 (5·0%) 1 (2·9%) 6 (13·3%) 1 (2·8%) [36] 
Stenotrophomonas maltophilia 0 0 0 1 (2·9%) 1 (2·2%) 2 (5·4%) 
Data at baseline and at final study visit are presented as no· of participants (% of total ·participants). 
*Data are presented as no. of newly emerged bacteria/macrolide-resistant bacteria (% of participants with newly emerged 
bacteria/macrolide-resistant bacteria out of participants with at least one follow-up visit, who were negative for the 
microorganism/macrolide-resistance at baseline). The number of participants available for the specific variables is stated in square brackets 
in the table cells if different from the total number of participants in the treatment group. 













Any adverse event 37 (78·7%) 31 (75·6%) 68 (77·3%) 
Serious adverse events       1 (2·1%)     3 (7·3%)     4 (4·5%) 
Most common adverse events 
 Non-per-protocol respiratory tract infections† 12 (25·5%) 8 (19·5%) 20 (22·7%) 
 Gastrointestinal    
  Abdominal pain 11 (23·4%) 4 (9·8%) 15 (17·0%) 
  Loose stools or diarrhoea 11 (23·4%)* 2 (4·9%) 13 (14·8%) 
  Gastroenteritis   7 (14·9%) 4 (9·8%) 11 (12·5%) 
  Nausea and/or vomiting   6 (12·8%) 3 (7·3%) 9 (10·2%) 
 Headache   7 (14·9%) 6 (14·6%) 13 (14·8%) 
 Fever   6 (12·8%) 4 (9·8%) 10 (11·4%) 
 Malaise   5 (10·6%) 5 (12·2%) 10 (11·4%) 
 Fatigue   4 (8·5%) 4 (9·8%) 8 (9·1%) 
 Pain in extremity   1 (2·1%)** 7 (17·1%) 8 (9·1%) 
 Middle ear inflammation   2 (4·3%) 4 (9·8%) 6 (6·8%) 
Data are presented as no. of participants with at least one event (% of total participants). *p=0·017, 
**p=0·023. 
The reported adverse events are those that either developed or increased in severity from receiving the 
initial dose of study drug until the 6-month visit or withdrawal from the study. The most common adverse 
events were defined as those that occurred in at least 10% of the participants in either treatment group.  








1. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent 
advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 
188: 913-22. 
2. Lucas JS, Burgess A, Mitchison HM, et al. Diagnosis and management of primary ciliary 
dyskinesia. Arch Dis Child 2014; 99: 850-6. 
3. Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on 
diagnostic and treatment approaches in children. Eur Respir J 2009; 34: 1264-76. 
4. Goutaki M, Meier AB, Halbeisen FS, et al. Clinical manifestations in primary ciliary dyskinesia: 
systematic review and meta-analysis. Eur Respir J 2016; 48: 1081-95. 
5. Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary 
ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181: 
1262-8. 
6. Strippoli MP, Frischer T, Barbato A, et al. Management of primary ciliary dyskinesia in 
European children: recommendations and clinical practice. Eur Respir J 2012; 39: 1482-91. 
7. Shapiro AJ, Zariwala MA, Ferkol T, et al. Diagnosis, monitoring, and treatment of primary 
ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr 
Pulmonol 2016; 51: 115-32. 
8. Werner C, Onnebrink JG, Omran H. Diagnosis and management of primary ciliary dyskinesia. 
Cilia 2015; 4: 2. 
9. Paff T, Daniels JM, Weersink EJ, Lutter R, Vonk Noordegraaf A, Haarman EG. A randomised 
controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur 
Respir J 2017; 49: 1601770. 
10. Koh YY, Park Y, Jeong JH, Kim CK, Min YG, Chi JG. The effect of regular salbutamol on lung 
function and bronchial responsiveness in patients with primary ciliary dyskinesia. Chest 2000; 117: 427-33. 
11. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with 
diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-32. 
12. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory 
disease. Eur Respir J 2013; 42: 239-51. 
13. Wilms EB, Touw DJ, Heijerman HG, van der Ent CK. Azithromycin maintenance therapy in 
patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. 
Pediatr Pulmonol 2012; 47: 658-65. 
14. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. 
Cochrane Database Syst Rev 2012; 11: CD002203. 
15. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-
cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 
380: 660-7. 
16. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on 
infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized 
controlled trial. JAMA 2013; 309: 1251-9. 
17. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with 
non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a 
multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 610-20. 
18. Kobbernagel HE, Buchvald FF, Haarman EG, et al. Study protocol, rationale and recruitment 
in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin 
maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med 2016; 16: 104. 
19. Lucas JS, Behan L, Dunn Galvin A, et al. A quality-of-life measure for adults with primary 





20. Dell SD, Leigh MW, Lucas JS, et al. Primary Ciliary Dyskinesia: First Health-related Quality-of-
Life Measures for Pediatric Patients. Ann Am Thorac Soc 2016; 13: 1726-35. 
21. Behan L, Leigh MW, Dell SD, Dunn Galvin A, Quittner AL, Lucas JS. Validation of a health-
related quality of life instrument for primary ciliary dyskinesia (QOL-PCD). Thorax 2017; 72: 832-9. 
22. Behan L, Leigh MW, Dell SD, Quittner AL, Hogg C, Lucas JS. Validation of pediatric health-
related quality of life instruments for primary ciliary dyskinesia (QOL-PCD). Pediatr Pulmonol 2019; 54: 
2011–20. 
23. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 
3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-43. 
24. Koopman M, Zanen P, Kruitwagen CL, van der Ent CK, Arets HG. Reference values for 
paediatric pulmonary function testing: The Utrecht dataset. Respir Med 2011; 105: 15-23. 
25. Verbanck S, Van Muylem A, Schuermans D, Bautmans I, Thompson B, Vincken W. Transfer 
factor, lung volumes, resistance and ventilation distribution in healthy adults. Eur Respir J 2016; 47: 166-76. 
26. Robinson P, Schechter MS, Sly PD, et al. Clarithromycin therapy for patients with cystic 
fibrosis: a randomized controlled trial. Pediatr Pulmonol 2012; 47: 551-7. 
27. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of 
azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006; 61: 895-
902. 
28. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function 
in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. 
JAMA 2010; 303: 1707-15. 
29. Sunther M, Bush A, Hogg C, McCann L, Carr SB. Recovery of baseline lung function after 
pulmonary exacerbation in children with primary ciliary dyskinesia. Pediatr Pulmonol 2016; 51: 1362-6. 
30. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis 
chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-
56. 
31. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. 
N Engl J Med 2011; 365: 689-98. 
32. Shah A, Shoemark A, MacNeill SJ, et al. A longitudinal study characterising a large adult 
primary ciliary dyskinesia population. Eur Respir J 2016; 48: 441-50. 
33. Green K, Buchvald FF, Marthin JK, Hanel B, Gustafsson PM, Nielsen KG. Ventilation 
inhomogeneity in children with primary ciliary dyskinesia. Thorax 2012; 67: 49-53. 
34. Kobbernagel HE, Green K, Ring AM, et al. One-year evolution and variability in multiple-
breath washout indices in children and young adults with primary ciliary dyskinesia. Eur Clin Respir J 2019; 
6: 1591841. 
35. Kent L, Reix P, Innes JA, et al. Lung clearance index: evidence for use in clinical trials in cystic 
fibrosis. J Cyst Fibros 2014; 13: 123-38. 
36. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose 
cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121: 3554-63. 
37. Lucas JS, Gahleitner F, Amorim A, et al. Pulmonary exacerbations in patients with primary 
ciliary dyskinesia: an expert consensus definition for use in clinical trials. ERJ Open Res 2019; 5: 00147-2018. 
 
